Application No.: 10/528,928 Attorney Docket No. PRD0032USPCT1
Reply to Office Action Dated: May 26, 2009 Page 2 of 13

I. AMENDMENTS

Amendments to the Claims:

Please replace all prior listing of claims with the following listing:

- 1. to 16. Canceled.
- 17. (New) A monoclonal antibody which specifically binds to a A β 11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length A β 1-40/42 peptide.
- 18. (New) The monoclonal antibody of claim 17, wherein said monoclonal antibody binds to human Aβ11-x.
- 19. (New) The monoclonal antibody of claim 17, wherein said monoclonal antibody binds to mouse $A\beta 11-x$.
- 20. (New) The monoclonal antibody of claim 17, which is detectably labeled.
- 21. (New) The monoclonal antibody of claim 21, wherein said detectable label is a radiolabel, an enzyme label, a luminescent label or a fluorescent label.
- 22. (New) The monoclonal antibody of claim 17, wherein said antibody is immobilized on a carrier.
- 23. (New) The monoclonal antibody of claim 17, which is mouse.
- 24. (New) The monoclonal antibody of claim 17, which is chimeric.
- 25. (New) The monoclonal antibody of claim 17, which is humanized.
- 26. (New) The monoclonal antibody of claim 17, which is produced by the hybridoma cell with the accession numbers LMBP 5896CB.

Application No.: 10/528,928 Attorney Docket No. PRD0032USPCT1
Reply to Office Action Dated: May 26, 2009 Page 3 of 13

27. (New) The monoclonal antibody of claim 17, which is produced by the hybridoma cell with the accession number LMBP 5897CB.

- 28. (New) A hybridoma which produces the monoclonal antibody of claim 17.
- 29. (New) The hybridoma of claim 28 which has the accession number LMBP 5896CB.
- 30. (New) The hybridoma of claim 28 which has the accession number LMBP 5897CB.
- 31. (New) A method for the determination or detection of A β 11-x peptide in a sample, the method comprising contacting the sample with the antibody of claim 17, and determining whether an immune complex is formed between the antibody and the A β 11-x peptide.
- 32. (New) The method of claim 31, wherein said sample is a tissue sample.
- 33. (New) The method of claim 31, wherein said sample is a bodily fluid.
- 34. (New) The method of claim 33, wherein said bodily fluid is selected from the group consisting of CSF, blood, plasma, serum and urine.
- 34. (New) A method for the diagnosis of Alzheimer's disease, comprising: obtaining a sample from a subject in need of said diagnosis; contacting said sample with an effective amount of said antibody of claim 20; detecting said label to determine the presence of A β 11-x peptides in said sample; and comparing an amount of A β 11-x peptides in said sample to an amount of A β 11-x peptides in a control, wherein an increased amount of A β 11-x peptides in said sample compared to the amount of A β 11-x peptides in the control indicates the presence of Alzheimer's disease.

Application No.: 10/528,928 Attorney Docket No. PRD0032USPCT1
Reply to Office Action Dated: May 26, 2009 Page 4 of 13

35. (New) A diagnostic composition comprising said antibody of claim 17 and a pharmaceutically acceptable carrier.